| Product NDC: | 31722-505 |
| Proprietary Name: | Nevirapine |
| Non Proprietary Name: | Nevirapine |
| Active Ingredient(s): | 200 mg/1 & nbsp; Nevirapine |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
| Product NDC: | 31722-505 |
| Labeler Name: | Camber Pharmaceuticals, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | ANDA078584 |
| Marketing Category: | ANDA |
| Start Marketing Date: | 20120523 |
| Package NDC: | 31722-505-01 |
| Package Description: | 100 TABLET in 1 BOTTLE (31722-505-01) |
| NDC Code | 31722-505-01 |
| Proprietary Name | Nevirapine |
| Package Description | 100 TABLET in 1 BOTTLE (31722-505-01) |
| Product NDC | 31722-505 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | Nevirapine |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20120523 |
| Marketing Category Name | ANDA |
| Labeler Name | Camber Pharmaceuticals, Inc. |
| Substance Name | NEVIRAPINE |
| Strength Number | 200 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC],Non-Nucleoside Analog [Chemical/Ingredient],Non-Nucleoside Reverse Transcriptase Inhibitors [MoA] |